Rajapillai L I Pillai1, Mengru Zhang2, Jie Yang3, Maura Boldrini4, J John Mann4, Maria A Oquendo5, Ramin V Parsey1, Christine DeLorenzo1,4. 1. Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA. 2. Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, USA. 3. Department of Family, Population, & Preventive Medicine, Stony Brook University, Stony Brook, NY, USA. 4. Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, New York, NY, USA. 5. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Positron emission tomography (PET) studies in major depressive disorder (MDD) have reported higher serotonin 1A (5-HT1A ) autoreceptor binding in the raphe. In males, the difference is so large that it can potentially be used as the first biological marker for MDD. However, the raphe includes several nuclei, which project to different regions of the brain and spinal cord and may be differentially involved in disease. We aimed to identify 5-HT1A differences in individual raphe nuclei using PET in order to determine whether use of subnuclei would provide greater sensitivity and specificity of diagnosing MDD. METHODS: We identified individual nuclei using a hybrid set-level technique on an average [11 C]-WAY100635 PET image derived from 52 healthy volunteers (HV). We delineated three nuclei: dorsal raphe nucleus (DRN), median raphe nucleus (MRN), and raphe magnus (RMg). An atlas image of these nuclei was created and nonlinearly warped to each subject (through an associated MRI) in a separate sample of 41 males (25 HV, 16 MDD) who underwent [11 C]-WAY100635 PET. RESULTS: 5-HT1A binding was elevated in DRN in MDD (P < .01), and was not different in the RMg and MRN between groups. Receiver operating characteristic (ROC) curves showed that combining DRN and MRN produces highest sensitivity (94%) and specificity (84%) to identify MDD. CONCLUSION: In agreement with postmortem studies, we found higher 5-HT1A autoreceptor binding in MDD selectively in the DRN. 5-HT1A autoreceptor binding in the combined DRN and MRN is a better biomarker for MDD than in the raphe as a whole.
BACKGROUND: Positron emission tomography (PET) studies in major depressive disorder (MDD) have reported higher serotonin 1A (5-HT1A ) autoreceptor binding in the raphe. In males, the difference is so large that it can potentially be used as the first biological marker for MDD. However, the raphe includes several nuclei, which project to different regions of the brain and spinal cord and may be differentially involved in disease. We aimed to identify 5-HT1A differences in individual raphe nuclei using PET in order to determine whether use of subnuclei would provide greater sensitivity and specificity of diagnosing MDD. METHODS: We identified individual nuclei using a hybrid set-level technique on an average [11 C]-WAY100635 PET image derived from 52 healthy volunteers (HV). We delineated three nuclei: dorsal raphe nucleus (DRN), median raphe nucleus (MRN), and raphe magnus (RMg). An atlas image of these nuclei was created and nonlinearly warped to each subject (through an associated MRI) in a separate sample of 41 males (25 HV, 16 MDD) who underwent [11 C]-WAY100635 PET. RESULTS:5-HT1A binding was elevated in DRN in MDD (P < .01), and was not different in the RMg and MRN between groups. Receiver operating characteristic (ROC) curves showed that combining DRN and MRN produces highest sensitivity (94%) and specificity (84%) to identify MDD. CONCLUSION: In agreement with postmortem studies, we found higher 5-HT1A autoreceptor binding in MDD selectively in the DRN. 5-HT1A autoreceptor binding in the combined DRN and MRN is a better biomarker for MDD than in the raphe as a whole.
Authors: Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: Ramin V Parsey; R Todd Ogden; Jeffrey M Miller; Adrienne Tin; Natalie Hesselgrave; Ellen Goldstein; Arthur Mikhno; Matthew Milak; Francesca Zanderigo; Gregory M Sullivan; Maria A Oquendo; J John Mann Journal: Biol Psychiatry Date: 2010-05-23 Impact factor: 13.382
Authors: John W Williams; Michael Pignone; Gilbert Ramirez; Christina Perez Stellato Journal: Gen Hosp Psychiatry Date: 2002 Jul-Aug Impact factor: 3.238
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Jeffrey M Miller; Kathleen G Brennan; Todd R Ogden; Maria A Oquendo; Gregory M Sullivan; J John Mann; Ramin V Parsey Journal: Neuropsychopharmacology Date: 2009-05-20 Impact factor: 7.853
Authors: Juan Joseph Young; Tim Silber; Davide Bruno; Isaac Robert Galatzer-Levy; Nunzio Pomara; Charles Raymond Marmar Journal: Front Psychiatry Date: 2016-04-25 Impact factor: 4.157
Authors: Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo Journal: Neuroimage Date: 2020-03-10 Impact factor: 6.556
Authors: Nadine M Melhem; Yongqi Zhong; Jeffrey M Miller; Francesca Zanderigo; R Todd Ogden; M Elizabeth Sublette; Madison Newell; Ainsley Burke; John G Keilp; Mohammad Lesanpezeshki; Elizabeth Bartlett; David A Brent; J John Mann Journal: Int J Neuropsychopharmacol Date: 2022-01-12 Impact factor: 5.176